References

Cystic fibrosis

10.1056/nejmra2216474 · 2023 · External reference

CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis

10.1016/s0140-6736(23)01609-4 · 2023 · External reference

VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles

10.1056/nejmoa1807120 · 2018 · External reference

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

10.1016/s0140-6736(19)32597-8 · 2019 · External reference

Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele

10.1056/nejmoa1908639 · 2019 · External reference

Unresolved reference

External reference

Cystic fibrosis patient registries: a valuable source for clinical research

10.1016/j.jcf.2018.03.001 · 2018 · External reference

Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial

10.1164/rccm.202108-1986oc · 2022 · External reference

Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study

10.1016/j.jcf.2023.03.002 · 2023 · External reference

Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis

10.1016/j.jcf.2022.12.009 · 2023 · External reference

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry

10.1016/j.lanepe.2023.100690 · 2023 · External reference

CFTR modulators therapy efficacy in reducing cystic fibrosis (CF) exacerbation and improving selected spirometry parameters: a real-life study in a single-centre polish population

10.3390/jcm13154491 · 2024 · External reference

Lung function improvement on triple modulators: high-resolution, nationwide data from the Danish Cystic Fibrosis Cohort

10.1183/23120541.00339-2024 · 2024 · External reference

698 real-world impact of elexacaftor/tezacaftor/ivacaftor on pulmonary and nutritional outcomes in people with cystic fibrosis

10.1016/s1569-1993(24)01536-4 · 2024 · External reference

Unresolved reference

2024 · External reference

The cystic fibrosis foundation patient registry. Design and methods of a National Observational Disease Registry

10.1513/annalsats.201511-781oc · 2016 · External reference

The impact of switching to race-neutral reference equations on FEV(1) percent predicted among people with cystic fibrosis

10.1016/j.jcf.2024.03.013 · 2024 · External reference

Obesity in cystic fibrosis: prevalence, trends and associated factors data from the US Cystic Fibrosis Foundation Patient registry

10.1016/j.jcf.2022.03.010 · 2022 · External reference

Lung function decline in cystic fibrosis: impact of data availability and modeling strategies on clinical interpretations

10.1513/annalsats.202209-829oc · 2023 · External reference

The effects of the COVID-19 pandemic on community respiratory virus activity

10.1038/s41579-022-00807-9 · 2023 · External reference

Factors associated with prescription of elexacaftor/tezacaftor/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele

10.1016/j.jcf.2024.10.006 · 2025 · External reference

Dornase alfa and progression of lung disease in cystic fibrosis

10.1002/ppul.20858 · 2008 · External reference

Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review

10.1016/j.jada.2008.02.020 · 2008 · External reference

Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study

10.3945/ajcn.112.051409 · 2013 · External reference

Nutritional considerations for a new era: a CF foundation position paper

10.1016/j.jcf.2023.05.010 · 2023 · External reference

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

10.1016/s2213-2600(22)00434-9 · 2023 · External reference

Using real-world research to study the impact of chronic daily therapy discontinuation in cystic fibrosis: the home reported outcomes in cystic fibrosis 2 (HERO-2) study design

10.1016/j.chpulm.2024.100080 · 2024 · External reference

Exploring reduced pulmonary exacerbation rates in cystic fibrosis: a pandemic or modulator effect?

10.1183/23120541.00111-2025 · 2025 · External reference